Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.48 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25019687 | 1.00 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNA7CHRNA5CHRNB4 | |
| SCHEMBL13531684 | 1.00 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNA7CHRNA5CHRNB4 | |
| SCHEMBL14049036 | 0.95 | CYP1A2 (0.44) | CHRNB2CHRNA4CHRNA7CHRNA5 | |
| SCHEMBL13531681 | 0.95 | CYP1A2 (0.44) | CHRNB2CHRNA4CHRNA7CHRNA5 | |
| SCHEMBL13531680 | 0.95 | CYP1A2 (0.44) | CHRNB2CHRNA4CHRNA7CHRNA5 | |
| SCHEMBL14401062 | 0.87 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA7CHRNA5CHRNB4 | |
| SCHEMBL15780666 | 0.84 | CYP1A2 (0.44) | CHRNB2CHRNA4CHRNA7CHRNA5 | |
| SCHEMBL13400532 | 0.82 | S1PR1 (0.49) | — | |
| SCHEMBL10241158 | 0.81 | S1PR1 (0.44) | — | |
| SCHEMBL14048821 | 0.81 | CYP1A2 (0.50) | CHRNB2CHRNA4CHRNA7CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567358-B2 | Methods of treatment using N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide | ASTRAZENECA AB (SE) | 2017-02-14 | — | — | US | disclosed |
| US-9018191-B2 | Phosphonoxy quinazoline derivatives and their pharmaceutical use | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2014-06-12 | — | — | US | disclosed |
| US-20100022476-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | US | disclosed |
| EP-1578755-B1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022476-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | CCNI, MKI67, TP53 | CHRNB2 4823/4885CHRNA4 4796/4885CHRNA7 4644/4885 |
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | PLK2, ABL1, CYP3A5 | CHRNB2 2576/4885CHRNA4 1740/4885CHRNA7 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.